

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7775788

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ASHER NATHAN	06/14/2017
MICHAL SHAHAR	06/14/2017
RECEIVING PARTY DATA	
Name:	NEOTX THERAPEUTICS LTD.
Street Address:	2 PEKERIS ST.
City:	REHOVOT
State/Country:	ISRAEL
Postal Code:	7670202
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16710432
CORRESPONDENCE DATA	
Fax Number:	(617)523-1231
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6175701000
Email:	MHarden@goodwinlaw.com, kbranzetti@goodwinlaw.com, US-PatentBos@goodwinlaw.com
Correspondent Name:	GOODWIN PROCTER LLP / IP DOCKETING DEPT.
Address Line 1:	100 NORTHERN AVENUE
Address Line 4:	BOSTON, MASSACHUSETTS 02210
ATTORNEY DOCKET NUMBER:	NTX-001C2
NAME OF SUBMITTER:	MARK HARDEN
SIGNATURE:	/Mark Harden/
DATE SIGNED:	02/02/2023
Total Attachments: 3	
source=NTX-001C2_Assignment#page1.tif	
source=NTX-001C2_Assignment#page2.tif	
source=NTX-001C2_Assignment#page3.tif	

**ASSIGNMENT AND CONFIRMATION OF ASSIGNMENT
OF PATENT RIGHTS**

WHEREAS, We, Asher Nathan and Michal Shahar ("ASSIGNORS"), have invented one or more inventions described in United States Provisional Patent Application No. 62/276,955, filed January 10, 2016, United States Patent Application No. 15/402,888, filed January 10, 2017, and International Patent Application No. PCT/IB2017/000511, filed January 10, 2017, all entitled "Methods and Compositions for Enhancing the Potency of Superantigen Mediated Cancer Immunotherapy," and

WHEREAS, NeoTX Therapeutics Ltd. (hereinafter "ASSIGNEE"), a corporation having a business address at 2 Pekeris St., Rehovot, 7670202, Israel, desires to acquire an interest therein, in accordance with agreements duly entered into with us;

NOW, THEREFORE, to all whom it may concern, be it known that for and in consideration of said agreements and of other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, we have sold, assigned and transferred and by these presents do hereby sell, assign and transfer unto said ASSIGNEE, its successors, assigns, and legal representatives, our entire right, title and interest, which ASSIGNEE accepts, in and throughout the United States of America, its territories and all foreign countries, in and to the invention(s) described in said application, together with our entire right, title and interest, which ASSIGNEE accepts, in and to said application and such Letters Patent as may issue thereon or claim priority under United States law or international convention, including but not limited to non-provisionals, continuations, continuations-in-part, divisionals, reissues, reexaminations, extensions, and substitutions of said application or such Letters Patent, and any right, title and interest we may have in provisional applications to which said application claims priority and the right to claim priority to the above reference provisional application for any such applications and Letters Patent; said inventions, applications and Letters Patent to be held and enjoyed by said ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held by us had this assignment and sale not been made; we hereby convey all of our rights arising under or pursuant to any and all United States laws and international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for Letters Patent, including but not limited to any cause(s) of action and damages accruing prior to this assignment. We hereby acknowledge that this assignment, being of our entire right, title and interest in and to said invention(s), carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all Letters Patent to ASSIGNEE in its own name as assignee of our entire right, title and interest therein;

AND, We hereby further agree for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid invention(s) to said ASSIGNEE, its successors, assigns, and legal representatives, but at its or their expense and charges, including

the execution of non-provisional, substitution, continuation, continuation-in-part, divisional, reissue, reexamination, or corresponding foreign or international patent applications;

AND, We hereby further agree to provide statements or testimony in any interference or other proceeding in which said invention(s) or any application or patent directed thereto may be involved;


AND, We hereby authorize ASSIGNEE or its attorneys or agents to insert the correct serial number and filing date into this assignment, if none is indicated on the date of our execution of this assignment;

AND, We hereby authorize and request the Director of the United States Patent and Trademark Office and the empowered officials of all other governments to issue such Letters Patent as shall be granted upon said application, or applications based thereon, to said ASSIGNEE, its successors, assigns, or legal representatives.

IN TESTIMONY WHEREOF, we, along with ASSIGNEE's legal representative, have hereunto set our hands and affixed our seals on the date(s) set forth below.


ASSIGNORS

June 14 2017
Date



Asher Nathan

Witness:

June 16 2017
Date



Signature
Name of Witness: lital fernandes

June 14 2017
Date


Michal Shahar

Witness:

JUNE 14, 2017
Date


Signature
Name of Witness: ROBERT HANOW

Accepted by:

ASSIGNEE'S AUTHORIZED REPRESENTATIVE

Date: JUNE 14, 2017

Signature: 

Representative's Name: ROBERT HANOW

Representative's Title: CFO

ACTIVE/90772605.1